Detalhe da pesquisa
1.
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
J Card Fail
; 30(1): 104-110, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37072105
2.
Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Drug Metab Dispos
; 51(4): 451-463, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36639243
3.
Inhibition of MPO (Myeloperoxidase) Attenuates Endothelial Dysfunction in Mouse Models of Vascular Inflammation and Atherosclerosis.
Arterioscler Thromb Vasc Biol
; 39(7): 1448-1457, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31043077
4.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Br J Clin Pharmacol
; 85(4): 762-770, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30618054
5.
Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque.
Eur Heart J
; 39(35): 3301-3310, 2018 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30219874
6.
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
J Med Chem
; 65(17): 11485-11496, 2022 09 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36005476
7.
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.
Int J Cardiol
; 365: 34-40, 2022 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35842004
8.
Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.
Kidney Int Rep
; 6(11): 2803-2810, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34805632
9.
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Clin Drug Investig
; 41(10): 895-905, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34546534
10.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Clin Transl Sci
; 14(3): 812-819, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32770730
11.
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
Clin Pharmacol Drug Dev
; 9(3): 411-421, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31793171
12.
Myeloperoxidase inhibition decreases morbidity and oxidative stress in mice with cystic fibrosis-like lung inflammation.
Free Radic Biol Med
; 152: 91-99, 2020 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-32142878
13.
Structural analysis identifies an escape route from the adverse lipogenic effects of liver X receptor ligands.
Commun Biol
; 2: 431, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31799433
14.
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
J Med Chem
; 62(9): 4312-4324, 2019 05 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30869888
15.
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Clin Transl Sci
; 11(3): 330-338, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29517132
16.
Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction".
J Med Chem
; 65(19): 13482, 2022 Oct 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36190771
17.
The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
Eur J Heart Fail
; 17(3): 273-82, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25684370